Propeller has been proven to work in clinical research studies and real-world commercial programs
More than 150 peer-reviewed publications and abstracts demonstrate effectiveness across diverse geographies, settings, and patient populations.
commercial programs & research studies
study participants
peer-reviewed publications & abstracts
Outcomes for patients with asthma
Improved medication adherence
Propeller provides consistently higher levels of medication adherence. Improved medication adherence may lead to a reduced risk of asthma exacerbations.Delea et al., (2008). Association between adherence with fixed dose combination fluticasone propionate/salmeterol on asthma outcomes and costs. Current medical research and opinio
Over six months, patients using Propeller had 58% higher adherence than those in the control group.Van Sickle et al., (2016). Randomized, controlled study of the impact of a mobile health tool on
asthma SABA use, control and adherence. 2016. Abstract presented at the European Respiratory Society
Study Design
Randomized controlled trial
Participants
125 adults with asthma
Based on objectively collected sensor data, controller-to-total medication ratio improved from 0.66 to 0.82, reflecting a shift toward higher adherence.Merchant et al., (2018). Impact of a Digital Health Intervention on Asthma Resource Utilization. WAOJ
Study Design
Pre-post quality improvement program
Participants
224 patients with asthma
Reduced rescue inhaler usage
Propeller has demonstrated reductions in rescue inhaler use in a number of studies and populations. Reductions in rescue inhaler use can be associated with better asthma control, more days without symptoms, and a better quality of life.
Propeller users experienced up to an 18.5% reduction in rescue inhaler use compared to a control group.Merchant et al., (2016). Effectiveness of population health management using the propeller health asthma platform: a randomized clinical trial. J Allergy Clin Immunol Pract
Study Design
Randomized controlled trial
Participants
495 adults and children with asthma
In a 3 month study, patients with asthma who used Propeller experienced 13% more SABA-free days.Mosnaim et al., (2021). The Impact of Patient Self-Monitoring Via Electronic Medication Monitor and Mobile App Plus Remote Clinician Feedback on Adherence to Inhaled Corticosteroids: A Randomized Controlled Trial. J Allergy Clin Immunol Pract
Study Design
Randomized controlled trial
Participants
100 adults with asthma
Return on investment
Research shows that uncontrolled asthma is expensive for patients, employers, payers, and clinicians.Yaghoubi et al., (2019). The projected economic and health burden of uncontrolled asthma in the United States. American journal of respiratory and critical care medicine
$1,349
per patient
Estimated annual excess direct costs associated with uncontrolled asthma
12.7%
Amount of work time lost compared with a person with controlled asthma
6.6
weeks
Lost productivity
during a year
Improved disease control
72% of participants using Propeller achieved asthma control (as defined by the Asthma Control TestTM) including 63% of adults who were initially uncontrolled.Merchant et al., (2016). Effectiveness of population health management using the propeller health asthma platform: a randomized clinical trial. J Allergy Clin Immunol Pract
Study design
Randomized controlled trial
Participants
495 adults and children with asthma
Reduced healthcare utilization
As Propeller users improve their medication adherence and asthma control, they may experience fewer hospitalizations and emergency department (ED) visits resulting in reduced healthcare costs.
Over 12 months, ED visits were reduced by 53% and ED visits and hospitalizations were reduced by 57%.3
Study Design
Pre-post quality improvement program
Participants
224 children and adults with asthma
Outcomes for patients with COPD
Reduced rescue inhaler usage
Reductions in rescue inhaler use may indicate more days without symptoms and a better quality of life.
At 12 months of use, Propeller users saw:Chen et al., (2019). Passive monitoring of short-acting beta-agonist use via digital platform in patients with chronic obstructive pulmonary disease: quality improvement retrospective analysis. JMIR
absolute improvement in rescue inhaler-free days
reduction in mean rescue inhaler puffs per day
reduction in nighttime rescue inhaler use
Study Design
Quality improvement program
Participants
190 Medicare-eligible adults with COPD
Identification of COPD patients at high risk
Data from the Propeller platform may help identify patients at greater risk of a COPD exacerbation, allowing clinicians to intervene to prevent a hospitalization or ED visit.Busse et al. (2022) Insights from the AUSTRI study on reliever use before and after asthma exacerbations. J Allergy Clin Immunol Pract
Reduced healthcare utilization
In 2010, the cost of COPD in the USA was approximately $50 billion. This included $20 billion in indirect costs and $30 billion in direct health care expenditures, with hospital stays accounting for the majority of these costs.Guarascio et al., (2013). The clinical and economic burden of chronic obstructive pulmonary disease in the USA. ClinicoEconomics and outcomes research: CEOR
In conjunction with disease management, COPD-related healthcare utilization was reduced by 35%.Alshabani et al., (2019). J. Electronic Inhaler Monitoring and Healthcare Utilization in Chronic Obstructive Pulmonary Disease. Telemedicine and Telecare
Study Design
Pre-post quality improvement study
Participants
39 patients with COPD who had at least one healthcare utilization (ED visit or hospitalization) in the past 12 months
Patient satisfaction
Patients with asthma and COPD expressed high levels of satisfaction with the Propeller experience.Merchant et al. (2018). Digital health intervention for asthma: patient-reported value and usability. JMIR mHealth and uHealth
Upon completion of a randomized controlled study of adults and children with asthma, 89 participants who received the intervention completed a satisfaction survey.
Of these 89 participants, 79% reported being very satisfied with the inhaler sensor device, while 20% reported being somewhat satisfied.
In addition, 93% expressed satisfaction with the reports, 90% found the information from the reports useful for learning about their asthma and 72% reported that they were interested in continuing to use the sensor and platform beyond the study.
In a retrospective study of participants with COPD, 84% (16/19) reported being highly satisfied or satisfied with the inhaler sensor device and monitoring.11
In a 3-month prospective study of participants with moderate-to-severe COPD, 74% (23/31) of participants reported satisfaction with the inhaler sensor device.Sumino et al. (2017). Use of a Remote Inhaler Monitoring Device to Measure Change in Inhaler Use with Chronic Obstructive Pulmonary Disease Exacerbations. J Aerosol Med Pulm Drug Deliv